Imaging of HCC

Abdominal Imaging

Volumn 37, Issue 2, 2012, Pages 215-230

  Ayuso, Carmen ^a   Rimola, Jordi ^a   García Criado, Ángeles ^a  

^a UNIVERSITY OF BARCELONA   (Spain)

Author keywords

Computed tomography; Diagnosis; Hepatocellular carcinoma; Magnetic resonance imaging; Percutaneous biopsy; Ultrasonography

Indexed keywords

GADOBENATE DIMEGLUMINE; GADOXETIC ACID; SORAFENIB; SUPERPARAMAGNETIC IRON OXIDE; YTTRIUM 90;

ARTICLE; ASPIRATION BIOPSY; CANCER PALLIATIVE THERAPY; CANCER STAGING; CHEMOEMBOLIZATION; CLINICAL DECISION MAKING; CONTRAST ENHANCEMENT; DIAGNOSTIC ACCURACY; DIAGNOSTIC IMAGING; EARLY DIAGNOSIS; ECHOGRAPHY; FOLLOW UP; HUMAN; LIVER CARCINOMA; LIVER CELL CARCINOMA; LIVER CIRCULATION; LIVER CIRRHOSIS; LIVER FUNCTION; LYMPH NODE METASTASIS; MULTIDETECTOR COMPUTED TOMOGRAPHY; NUCLEAR MAGNETIC RESONANCE IMAGING; PATIENT MONITORING; PRIORITY JOURNAL; PROGNOSIS; RADIOEMBOLIZATION; RADIOFREQUENCY ABLATION; TREATMENT INDICATION; TREATMENT PLANNING; TREATMENT RESPONSE;

ALGORITHMS; BIOPSY; CARCINOMA, HEPATOCELLULAR; CHOLANGIOGRAPHY; CONTRAST MEDIA; HUMANS; IMAGE ENHANCEMENT; IMAGE INTERPRETATION, COMPUTER-ASSISTED; LIVER NEOPLASMS; MAGNETIC RESONANCE IMAGING; NEOPLASM STAGING; SENSITIVITY AND SPECIFICITY; TOMOGRAPHY, X-RAY COMPUTED; ULTRASONOGRAPHY;

EID: 84863727012     PISSN: 09428925     EISSN: 14320509     Source Type: Journal    
DOI: 10.1007/s00261-011-9794-x     Document Type: Article

References (69)

1. Parkin DM, Bray F, Ferlay J, Pisani P (2005) Global cancer statistics, 2002. CA Cancer J Clin 55:74-108 (Pubitemid 40372904)
2. Sangiovanni A, Prati GM, Fasani P, et al. (2006) The natural history of compensated cirrhosis due to hepatitis C virus: a 17-year cohort study of 214 patients. Hepatology 43:1303-1310 (Pubitemid 43980109)
3. Llovet JM, Bruix J (2008) Novel advancements in the management of hepatocellular carcinoma in 2008. J Hepatol 48:S20-S37
4. Llovet JM, Burroughs A, Bruix J (2003) Hepatocellular carcinoma. Lancet 362:1907-1917 (Pubitemid 37518510)
5. Llovet JM, Fuster J, Bruix J (1999) Intention-to-treat analysis of surgical treatment for early hepatocellular carcinoma: resection versus transplantation. Hepatology 30:1434-1440
6. Bruix J, Sherman M (2010) Management of hepatocellular carcinoma: an update. American Association for the Study of Liver Diseases. http://www.aasld.org/practiceguidelines. Retrieved 4 October 2010.
7. Sherman M (2001) Alphafetoprotein: an obituary. J Hepatol 34:603-605 (Pubitemid 32328519)
8. Bolondi L (2003) Screening for hepatocellular carcinoma in cirrhosis. J Hepatol 39:1076-1084 (Pubitemid 37523784)
9. Brenner DJ, Hall EJ (2007) Computed tomography-an increasing source of radiation exposure. N Engl J Med 357:2277-2284 (Pubitemid 350190758)
10. Burrel M, Llovet JM, Ayuso C, et al. (2003) MRI angiography is superior to helical CT for detection of HCC prior to liver transplantation: an explant correlation. Hepatology 38:1034-1042 (Pubitemid 37221687)
11. Lencioni R, Cioni D, Pina C, Crocetti L, Bartolozzi C (2005) Hepatocellular carcinoma. Imaging diagnosis. Semin Liver Dis 25:162-170
12. Teefey SA, Hildeboldt CC, Dehdashti F, et al. (2003) Detection of primary hepatic malignancy in liver transplant candidates: prospective comparison of CT, MR imaging, US and PET. Radiology 226:533-542 (Pubitemid 36313446)
13. Trevisani F, De NS, Rapaccini G, et al. (2002) Semiannual and annual surveillance of cirrhotic patients for hepatocellular carcinoma: effects on cancer stage and patient survival (Italian experience). Am J Gastroenterol 97:734-744 (Pubitemid 34245906)
14. Kojiro M, Roskams T (2005) Early hepatocellular carcinoma and dysplastic nodules. Semin Liver Dis 25:133-142 (Pubitemid 40781066)
15. Lee MW, Kim YJ, Park HS, et al. (2010) Targeted sonography for small hepatocellular carcinoma discovered by CT or MRI: factors affecting sonographic detection. AJR Am J Roentgenol 194: W396-W400
16. Terminology of nodular hepatocellular lesions. International Working Party. Hepatology 22:983-993 (1995)
17. Kojiro M, Wanless IR, Alves V, et al. (2009) Pathologic diagnosis of early hepatocellular carcinoma: a report of the international consensus group for hepatocellular neoplasia. Hepatology 658-664
18. Hayashi M, Matsui O, Ueda K, et al. (1999) Correlation between the blood supply and grade of malignancy of hepatocellular nodules associated with liver cirrhosis: evaluation by CT during intraarterial injection of contrast medium. AJR Am J Roentgenol 172:969-976 (Pubitemid 29505622)
19. Efremidis SC, Hytiroglou P (2002) The multistep process of hepatocarcinogenesis in cirrhosis with imaging correlation. Eur Radiol 12:753-764 (Pubitemid 36940129)
20. KudoM(2009) Multistep human hepatocarcinogenesis: correlation of imaging with pathology. J Gastroenterol 44:112-118
21. Roncalli M, Roz E, Coggi G, et al. (1999) The vascular profile of regenerative and dysplastic nodules of the cirrhotic liver: implications for diagnosis and classification. Hepatology 30:1174-1178 (Pubitemid 29510855)
22. Kitao A, Zen Y, Matsui O, Gabata T, Nakamura Y (2009) Hepatocarcinogenesis: multistep changes of drainage vessels at CT during arterial portography and hepatic arteriography-radiologicpathologic correlation. Radiology 252:605-614
23. Huppertz A, Haraida S, Kraus A, et al. (2005) Enhancement of focal liver lesions at gadoxetic acid-enhanced MR imaging: correlation with histopathologic findings and spiral CT-initial observations. Radiology 234:468-478 (Pubitemid 40139918)
24. Frericks B, Loddenkemper CH, Huppertz A, et al. (2009) Qualitative and quantitative evaluation of hepatocellular carcinoma and cirrhotic liver enhancement using Gd-EOB-DTPA. AJR Am J Roentgenol 193:1053-1060
25. Kogita S, Imai Y, Okada M, et al. (2010) Gd-EOB-DTPA-enhanced magnetic resonance images of hepatocellular carcinoma: correlation with histological grading and portal blood flow. Eur Radiol 20(10):2405-2413
26. Bruix J, Sherman M, Llovet JM, et al. (2001) Clinical management of hepatocellular carcinoma. Conclusions of the Barcelona-2000 EASL conference. European Association for the Study of the Liver. J Hepatol 35:421-430 (Pubitemid 32844200)
27. Bruix J, Sherman M (2005) Management of hepatocellular carcinoma. Hepatology 42:1208-1236 (Pubitemid 43112690)
28. Forner A, Vilana R, Ayuso C, et al. (2008) Diagnosis of hepatic nodules £20 mm in cirrhosis. Prospective validation of the noninvasive diagnostic criteria for hepatocellular carcinoma (HCC). Hepatology 47:97-104 (Pubitemid 351171046)
29. Sangiovanni A, Manini MA, Iavarone M, et al. (2010) The diagnostic and economic impact of contrast imaging technique in the diagnosis of small hepatocellular carcinoma in cirrhosis. Gut 59:570-571
30. Bhayana D, Kim TK, Jang HJ, Burns PN, Wilson SR (2010) Hypervascular liver masses on contrast-enhanced ultrasound: the importance of washout. AJR Am J Roentgenol 194:977-983
31. Chen LD, Xu HX, Xie XY, et al. (2010) Intrahepatic cholangiocarcinoma and hepatocellular carcinoma: differential diagnosis with contrast-enhanced ultrasound. Eur Radiol 20:743-753
32. Vilana R, Forner A, Bianchi L, et al. (2010) Intrahepatic peripheral cholangiocarcinoma in cirrhotic patients may display a vascular pattern similar to hepatocellular carcinoma on contrast enhanced ultrasound. Hepatology 51:2020-2029
33. Rimola J, Forner A, Reig M, et al. (2009) Cholangiocarcinoma in cirrhosis: absence of contrast washout in delayed phases by MR avoids misdiagnosis of hepatocellular carcinoma. Hepatology 50:791-798
34. Bolondi L, Gaiani S, Celli N, et al. (2005) Characterization of small nodules in cirrhosis by assessment of vascularity: the problem of hypovascular hepatocellular carcinoma. Hepatology 42:27-34 (Pubitemid 40911308)
35. Ishigami K, Yoshimitsu K, Nishihara Y, et al. (2009) Hepatocellular carcinoma with a pseudocapsule on gadolinium enhanced MR images: correlation with histopathologic findings. Radiology 50:435-443
36. Martín J, Sentís M, Zidan A, et al. (1995) Fatty metamorphosis of hepatocellular carcinoma: detection with chemical shift gradientecho MR imaging. Radiology 195(1):125-130
37. Vandecaveye V, De Keyzer F, Verslype Ch, et al. (2009) Diffusionweighted MRI provides additional value to conventional dynamic contrast-enhanced MRI for detection of hepatocellular carcinoma. Eur Radiol 19:2456-2466
38. Kim YK, Kwak HS, Kim CS, et al. (2006) Hepatocellular carcinoma in patients with chronic liver disease: comparison of SPIOenhanced MR imaging and 16-detector row CT. Radiology 238:531-541 (Pubitemid 43134365)
39. Kim YK, Kim CS, Chung GH, et al. (2006) Comparison of gadobenate dimeglumine-enhanced dynamic MRI and 16-MDCT for the detection of hepatocellular carcinoma. AJR Am J Roentgenol 186:149-157
40. Kim SH, Kim SH, Lee J, et al. (2009) Gadoxetic acid-enhanced MRI versus triple-phase MDCT for the preoperative detection of hepatocellular carcinoma. AJR Am J Roentgenol 192:1675-1681
41. Filippone A, Blakeborough A, Breuer J, et al. (2010) Enhancement of liver parenchyma after injection of hepatocyte-specific MRI contrast media: a comparison of gadoxetic acid and gadobenate dimeglumine. J Magn Reson Imaging 31:356-364
42. Tsuboyama T, Onishi H, Kim T, et al. (2010) Hepatocellular carcinoma: hepatocyte-selective enhancement at gadoxetic acidenhancedMRimaging- correlationwith expression of sinusoidal and canalicular transporters and bile accumulation. Radiology 255(3): 824-833
43. Lee JY, Kim SH, Jeon YH, et al. (2010) Ferucarbotran-enhanced magnetic resonance imaging versus gadoxetic acid-enhanced magnetic resonance imaging for the preoperative detection of hepato- cellular carcinoma: initial experience. J Comput Assist Tomogr 34(1):127-134
44. Ahn SS, Kim MJ, Lim JS, et al. (2010) Added value of gadoxetic acid-enhanced hepatobiliary phase MR imaging in the diagnosis of hepatocellular carcinoma. Radiology 255:459-466
45. Motosugi U, Ichikawa T, Sou H, et al. (2010) Distinguishing hypervascular pseudolesions of the liver from hypervascular hepatocellular carcinomas with gadoxeticacid-enhanced MR imaging. Radiology 256(1):151-158
46. Sun HY, Lee JM, Shin CH, Lee DH (2010) Gadoxetic acid-enhanced magnetic resonance imaging for differentiating small hepatocellular carcinomas (≤2 cm in diameter) from arterial enhancing pseudolesions. Special emphasis on hepatobiliary phase imaging. Invest Radiol 45:96-103
47. Bruix J, Llovet JM (2009) Major achievements in hepatocellular carcinoma. Lancet 373:614-616
48. Llovet JM, Schwartz M, Mazzaferro V (2005) Resection and liver transplantation for hepatocellular carcinoma. Semin Liver Dis 25(2):181-200 (Pubitemid 40781071)
49. World Health Organization (1979) WHO handbook for reporting results of cancer treatment. Geneva (Albany, N.Y.: World Health Organization; sold by WHO Publications Centre USA)
50. Therasse P, Arbuck SG, Eisenhauer EA, et al. (2000) New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 92(3):205-216
51. Forner A, Ayuso C, Varela M, et al. (2009) Evaluation of tumor response after locoregional therapies in hepatocellular carcinoma: are response evaluation criteria in solid tumors reliable? Cancer 115(3):616-623
52. Goldberg SN, Grassi CJ, Cardella JF, et al. (2005) Image-guided tumor ablation: standardization of terminology and reporting criteria. Radiology 235(3):728-739 (Pubitemid 40695866)
53. Lencioni R, Llovet JM (2010) Modified RECIST (mRECIST) assessment for hepatocellular carcinoma. Semin Liver Dis 30(1):52-60
54. Cho YK, Kim JK, Kim WT, Chung JW (2010) Hepatic resection versus radiofrequency ablation for very early stage hepatocellular carcinoma: a Markov model analysis. Hepatology 51(4):1284-1290
55. Orlando A, Leandro G, Olivo M, Andriulli A, Cottone M (2009) Radiofrequency thermal ablation vs. percutaneous ethanol injection for small hepatocellular carcinoma in cirrhosis: meta-analysis of randomized controlled trials. Am J Gastroenterol 104(2):514-524
56. Dodd GD 3rd, Soulen MC, Kane RA, et al. (2000) Minimally invasive treatment of malignant hepatic tumors: at the threshold of a major breakthrough. Radiographics 20(1):9-27
57. Lu DS, Yu NC, Raman SS, et al. (2005) Radiofrequency ablation of hepatocellular carcinoma: treatment success as defined by histologic examination of the explanted liver. Radiology 234(3):954-960 (Pubitemid 40250843)
58. Vilana R, Bianchi L, Varela M, et al. (2006) Is microbubble-enhanced ultrasonography sufficient for assessment of response to percutaneous treatment in patients with early hepatocellular carcinoma? EurRadiol 16(11):2454-2462 (Pubitemid 44649694)
59. Kim SK, Lim HK, Kim YH, et al. (2003) Hepatocellular carcinoma treated with radio-frequency ablation: spectrum of imaging findings. Radiographics 23(1):107-121 (Pubitemid 37421439)
60. Sala M, Llovet JM, Vilana R, et al. (2004) Initial response to percutaneous ablation predicts survival in patients with hepatocellular carcinoma. Hepatology 40(6):1352-1360 (Pubitemid 39657009)
61. Hong K, Kobeiter H, Georgiades CS, Torbenson MS, Geschwind JF (2005) Effects of the type of embolization particles on carboplatin concentration in liver tumors after transcatheter arterial chemoembolization in a rabbit model of liver cancer. J Vasc Interv Radiol 16(12):1711-1717 (Pubitemid 44431170)
62. Takayasu K, Arii S, Matsuo N, et al. (2000) Comparison of CT findings with resected specimens after chemoembolization with iodized oil for hepatocellular carcinoma. AJR Am J Roentgenol 175(3):699-704
63. Kloeckner R, Otto G, Biesterfeld S, et al. (2010) MDCT versus MRI assessment of tumor response after transarterialchemoembolization for the treatment of hepatocellular carcinoma. Cardiovasc Intervent Radiol 33(3):532-540
64. Riaz A, Kulik L, Lewandowski RJ, et al. (2009) Radiologic-pathologic correlation of hepatocellular carcinoma treated with internal radiation using yttrium-90 microspheres. Hepatology 49(4):1185-1193
65. Salem R, Thurston KG (2006) Radioembolization with 90yttrium microspheres: a state-of-the-art brachytherapy treatment for primary and secondary liver malignancies. Part 2: special topics. J Vasc Interv Radiol 17(9):1425-1439 (Pubitemid 44412994)
66. Llovet JM, Ricci S, Mazzaferro V, et al. (2008) Sorafenib in advanced hepatocellular carcinoma. N Engl J Med 359(4):378-390
67. Cheng AL, Kang YK, Chen Z, et al. (2009) Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial. Lancet Oncol 10(1):25-34
68. Sahani DV, Holalkere NS, Mueller PR, Zhu AX (2007) Advanced hepatocellular carcinoma: CT perfusion of liver and tumor tissue- initial experience. Radiology 243(3):736-743 (Pubitemid 46799427)
69. Schraml C, Schwenzer NF, Martirosian P, et al. (2009) Diffusionweighted MRI of advanced hepatocellular carcinoma during sorafenib treatment: initial results. AJR Am J Roentgenol 193(4):W301-W307